B
TEVA icon

Baird’s Teva Pharmaceuticals TEVA Stock Holding History

Baird’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$9.49M Sell
152,302
-485,554
-76% -$28.2M 0.1% 217
2014
Q4 		$36.7M Buy
637,856
+612,832
+2,449% +$34.1M 0.39% 74
2014
Q3 		$1.34M Sell
25,024
-1,085
-4% -$57.5K 0.02% 562
2014
Q2 		$1.37M Buy
26,109
+274
+1% +$14K 0.02% 588
2014
Q1 		$1.36M Buy
25,835
+4,354
+20% +$201K 0.02% 554
2013
Q4 		$861K Buy
21,481
+952
+5% +$37.5K 0.01% 661
2013
Q3 		$776K Buy
20,529
+25
+0.1% +$975 0.01% 645
2013
Q2 		$804K Buy
+20,504
New +$798K 0.02% 624

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Baird's TEVA Position: Q1 2015 in Review

Baird reduced its Teva Pharmaceuticals (TEVA) stake by 76% in Q1 2015, selling an estimated $28.2M and leaving 152,302 shares worth $9.49M. The position accounts for 0.1% of the portfolio, ranked #217.

Baird first reported a position in TEVA in Q2 2013 and has held it in 8 quarters since. The position peaked at $36.7M in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

  • Baird held 152,302 shares of Teva Pharmaceuticals worth $9.49M as of Q1 2015.
  • Baird sold 485,554 Teva Pharmaceuticals shares in Q1 2015, an estimated $28.2M.
  • Teva Pharmaceuticals made up 0.1% of Baird's portfolio in Q1 2015, its #217 holding.
  • Baird first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
  • Baird's Teva Pharmaceuticals position peaked at $36.7M in Q4 2014.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.